IDH突变型2级胶质瘤唤醒功能定位手术前后难治性癫痫:105例连续病例分析
该回顾性研究纳入105例IDH突变型2级胶质瘤患者(共134次唤醒功能定位手术),分析术前和/或术后难治性癫痫对肿瘤功能结局的影响。结果显示肿瘤位置、术前体积和切除程度与围手术期难治性癫痫相关,而术后癫痫控制与KPS及复工率相关。
要点
- 岛叶/边缘系统肿瘤术后癫痫完全控制比例更高,中央区肿瘤术后难治性癫痫比例更高。
- 术前肿瘤体积更大和切除程度更低与难治性癫痫相关。
- 术后无癫痫发作患者KPS和复工率更高,提示癫痫控制影响功能结局。
核心结论
- 2级胶质瘤位置、肿瘤体积和切除程度与围手术期难治性癫痫相关,后者与生活质量(尤其KPS和复工)相关。
研究设计与样本
- 回顾性研究纳入2002年6月至2024年3月接受唤醒功能定位切除的IDH突变型2级胶质瘤患者,术前和/或术后有难治性癫痫且随访>1年,共105例(61例男性,58.1%),平均年龄35.6±12.2岁,共134次唤醒手术。
主要发现
- 诊断时101例(96.2%)有癫痫发作,82例(78.1%)有难治性癫痫。
- 术后60例(57.1%)完全无癫痫发作(Engel IA,组1),45例(42.8%)术后有难治性癫痫(组2 22例[21.0%],组3 23例[21.9%])。
- 组1岛叶/边缘系统肿瘤比例更高(p=0.002),组2和组3中央区肿瘤比例更高(p=0.01)。
- 术前肿瘤体积更大(p<0.00001)和切除程度更低(p=0.05)与难治性癫痫相关。
- 组1术后KPS(p<0.00002)和复工率(p=0.0004)更高。
关键数值与推荐
- 平均术前KPS 88.7±7.4,术后KPS 89.2±6.4;仅1例(0.9%)术后持续恶化。
- 平均切除程度86.8%±8.3%(平均残余体积13±18.4 cm3)。
- 平均随访8.3±4.7年,总生存率70.5%。
- 61例(82.4%)复工;22例(21.0%)接受即刻辅助治疗,29例(27.6%)再次手术。
临床怎么用
- 对于IDH突变型2级胶质瘤伴难治性癫痫患者,应综合评估肿瘤位置、体积和可切除程度以平衡癫痫控制与肿瘤切除。
- 术后癫痫控制与KPS和复工相关,提示围手术期癫痫管理是功能保护的重要环节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Awake resection in grade 2 glioma (G2G) improves quality of life (QOL) and overall survival (OS). Nonetheless, epilepsy occurs frequently in this context and can impair QOL, especially when the disorder is pharmacoresistant. Herein, the goal was to study patients with intractable epilepsy (IE) before and/or after surgery for a G2G. METHODS: Patients who underwent awake functional mapping-based resection of an IDH-mutant G2G in the period from June 2002 to March 2024 and had IE before and/or after surgery (follow-up > 1 year) were selected for this retrospective study. Onco-functional outcomes were compared among patients with preoperative IE who were completely seizure free (Engel class IA) postoperatively (group 1), patients with preoperative and postoperative IE (group 2), and patients who experienced IE only postoperatively (group 3). RESULTS: In a consecutive series of 105 patients (61 males [58.1%]) with a mean age of 35.6 ± 12.2 years, 134 awake surgeries were performed. At diagnosis, 101 patients (96.2%) presented with seizures, and 82 patients (78.1%) presented with IE. The mean preoperative Karnofsky Performance Status (KPS) was 88.7 ± 7.4, and 74 patients (70.5%) were able to work preoperatively. Sixty-three gliomas (60%) were left-sided and 42 were right-sided, which consisted of 66 insula-centered/paralimbic (62.8%), 13 central (12.4%), 14 frontal (13.3%), 6 temporal (5.7%), and 6 parietal (5.7%) tumors. The mean preoperative tumor volume was 82.8 ± 47.9 cm3. Only 1 patient (0.9%) had persistent postoperative deterioration, and the mean postoperative KPS was 89.2 ± 6.4. Sixty-one patients returned to work (82.4%). The mean extent of resection (EOR) was 86.8% ± 8.3% (mean residual volume 13 ± 18.4 cm3). Histopathologically, there were 65 astrocytomas (61.9%) and 40 oligodendrogliomas (38.1%). Twenty-two patients (21.0%) had immediate adjuvant therapy, and 29 patients (27.6%) underwent reoperation(s). The mean follow-up was 8.3 ± 4.7 years with an OS rate of 70.5%. Sixty patients (57.1%) were completely seizure free after surgery (group 1), and 45 patients (42.8%) had postoperative IE (22 patients [21.0%] in group 2 and 23 patients [21.9%] in group 3). The proportion of insula-centered/paralimbic G2Gs was higher in group 1 (p = 0.002), whereas the percentage of central G2Gs was greater in groups 2 and 3 (p = 0.01). Higher preoperative tumor volume (p < 0.00001) and lower EOR (p = 0.05) were correlated to IE. The postoperative KPS (p < 0.00002) and return to work (RTW) rate (p = 0.0004) were higher in group 1. CONCLUSIONS: These original findings show that G2G location, tumor volume, and EOR are associated with perioperative IE, itself correlated to QOL, especially KPS and RTW. Such data may help neurosurgeons better evaluate the epilepto-onco-functional balance of surgery in G2G.
引用
- Ng S, Duffau H. Intractable epilepsy before and/or after awake functional mapping-based surgery for IDH-mutant grade 2 glioma: a consecutive series of 105 patients. J Neurosurg. 2026. PMID: 42102408. doi:10.3171/2025.12.JNS251916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。